Michelson Diagnostics issues preliminary specification for OCT probe

31 January 2009

The OCT probe Michelson Diagnostics has issued a preliminary specification for its clinical Optical Coherence Tomography (OCT) probe and processing system, which the company says is planned for launch in late spring 2009. The new OCT system has been given the name ‘Vivosight’.

Two variants of the new Vivosight probe are specified, one is a version with X-Y scanning, to enable 3D mapping of flat tissue such as skin, and the other is a version equipped with a rigid endoscope, suitable for internal applications. The unique multi-beam design provides double the image resolution (ie better than 10 μm) available from conventional single-beam designs, resulting in crisper, clearer OCT images, showing more clinical detail.

“We will be applying for a CE-mark for the product, which will enable sales for clinical use in Europe, in the spring 2009 time-frame.” said Jon Holmes, Chief Executive, “This will be followed by a 510(k) for the
equivalent in the US market.”

Bookmark this page

Your browser does not support inline frames or is currently configured not to display inline frames.	Your browser does not support inline frames or is currently configured not to display inline frames. Michelson Diagnostics issues preliminary specification for OCT probe 31 January 2009 Michelson Diagnostics has issued a preliminary specification for its clinical Optical Coherence Tomography (OCT) probe and processing system, which the company says is planned for launch in late spring 2009. The new OCT system has been given the name ‘Vivosight’. Two variants of the new Vivosight probe are specified, one is a version with X-Y scanning, to enable 3D mapping of flat tissue such as skin, and the other is a version equipped with a rigid endoscope, suitable for internal applications. The unique multi-beam design provides double the image resolution (ie better than 10 μm) available from conventional single-beam designs, resulting in crisper, clearer OCT images, showing more clinical detail. “We will be applying for a CE-mark for the product, which will enable sales for clinical use in Europe, in the spring 2009 time-frame.” said Jon Holmes, Chief Executive, “This will be followed by a 510(k) for the equivalent in the US market.” Bookmark this page Your browser does not support inline frames or is currently configured not to display inline frames. To top	Your browser does not support inline frames or is currently configured not to display inline frames.